NMDA Blockade Changed Acute THC Antinociception but Did Not Prevent Tolerance in a Mouse Protocol
In a mouse experiment, MK-801 reduced acute THC antinociception without preventing later tolerance to that effect or to hypothermia. Nitric oxide synthase inhibition also failed to modify the reported THC outcomes.
Acute effects were endpoint-specific
Male Swiss-Webster mice received THC with or without the NMDA antagonist MK-801. The antagonist attenuated antinociception across tested comparisons but did not similarly change the temperature-lowering effect. An intervention altering one acute response therefore did not broadly block THC pharmacology.
The repeated-exposure result was negative
Twice-daily THC over four days produced antinociceptive and temperature tolerance. MK-801 pretreatment did not prevent either form of tolerance under this regimen. L-NMMA, a nitric oxide synthase inhibitor, did not alter the reported acute effects or tolerance development. Those null findings belong to the tested doses, timing and assays.
Mechanistic extrapolation requires matching the experiment
NMDA or nitric-oxide involvement in another cannabinoid study would not guarantee the same result here. Different compounds, exposure routes and interventions can address different parts of adaptation. The supplied abstract is truncated, so conclusions should remain within the comparisons actually described rather than assuming additional unreported results.
The study separates changing an immediate drug effect from preventing adaptation to repeated exposure. It does not establish that these pathways never contribute to cannabinoid tolerance, nor does it provide a clinical intervention. Preserving the acute-positive and chronic-null distinction is the central interpretive point.
Related: interpreting cannabis tolerance claims.
Research cited
Thorat SN; Bhargava HN. Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in mice. Brain research (1994). doi:10.1016/0006-8993(94)91715-9. Findings discussed from the study abstract.
